Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2013 Apr 25:8:100.
doi: 10.1186/1748-717X-8-100.

Vascular endothelial growth factor (VEGF) expression in locally advanced prostate cancer: secondary analysis of radiation therapy oncology group (RTOG) 8610

Larry Pan  1 , Seunghee Baek, Pamela R Edmonds, Mack Roach 3rd, Harvey Wolkov, Satish Shah, Alan Pollack, M Elizabeth Hammond, Adam P Dicker
Affiliations

Vascular endothelial growth factor (VEGF) expression in locally advanced prostate cancer: secondary analysis of radiation therapy oncology group (RTOG) 8610

Larry Pan et al. Radiat Oncol. .

Abstract

Background: Angiogenesis is a key element in solid-tumor growth, invasion, and metastasis. VEGF is among the most potent angiogenic factor thus far detected. The aim of the present study is to explore the potential of VEGF (also known as VEGF-A) as a prognostic and predictive biomarker among men with locally advanced prostate cancer.

Methods: The analysis was performed using patients enrolled on RTOG 8610, a phase III randomized control trial of radiation therapy alone (Arm 1) versus short-term neoadjuvant and concurrent androgen deprivation and radiation therapy (Arm 2) in men with locally advanced prostate carcinoma. Tissue samples were obtained from the RTOG tissue repository. Hematoxylin and eosin slides were reviewed, and paraffin blocks were immunohistochemically stained for VEGF expression and graded by Intensity score (0-3). Cox or Fine and Gray's proportional hazards models were used.

Results: Sufficient pathologic material was available from 103 (23%) of the 456 analyzable patients enrolled in the RTOG 8610 study. There were no statistically significant differences in the pre-treatment characteristics between the patient groups with and without VEGF intensity data. Median follow-up for all surviving patients with VEGF intensity data is 12.2 years. Univariate and multivariate analyses demonstrated no statistically significant correlation between the intensity of VEGF expression and overall survival, distant metastasis, local progression, disease-free survival, or biochemical failure. VEGF expression was also not statistically significantly associated with any of the endpoints when analyzed by treatment arm.

Conclusions: This study revealed no statistically significant prognostic or predictive value of VEGF expression for locally advanced prostate cancer. This analysis is among one of the largest sample bases with long-term follow-up in a well-characterized patient population. There is an urgent need to establish multidisciplinary initiatives for coordinating further research in the area of human prostate cancer biomarkers.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Univariate proportional hazards regression analysis for overall survival.
Figure 2
Figure 2
Univariate proportional hazards regression analysis for distant metastasis.
Figure 3
Figure 3
Univariate proportional hazards regression analysis for local progression.
Figure 4
Figure 4
Univariate proportional hazards regression analysis for disease-free survival.
Figure 5
Figure 5
Univariate proportional hazards regression analysis for biochemical failure.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Jemal A, Siegel R, Ward E. Cancer statistics, 2007. CA Cancer J Clin. 2007;57(1):43–66. doi: 10.3322/canjclin.57.1.43. - DOI - PubMed
    1. Pandya NM, Dhalla NS, Santani DD. Angiogenesis – a new target for future therapy. Vascular Pharmacol. 2006;44(5):265–274. doi: 10.1016/j.vph.2006.01.005. - DOI - PubMed
    1. McMahon G. VEGF receptor signaling in tumor angiogenesis. Oncologist. 2000;5(Suppl 1):3–10. - PubMed
    1. Byrne AM, Bouchier-Hayes DJ, Harmey JH. Angiogenic and cell survival functions of vascular endothelial growth factor (VEGF) J Cell Mol Med. 2005;9(4):777–794. doi: 10.1111/j.1582-4934.2005.tb00379.x. - DOI - PMC - PubMed
    1. Steiner MS. Role of peptide growth factors in the prostate: a review. Urology. 1993;42(1):99–110. doi: 10.1016/0090-4295(93)90352-B. - DOI - PubMed

Publication types

MeSH terms